Heart failure, Hyperuricemia
Conditions
Interventions
Group A:Benzbromarone 50mg-100mg once daily.
Group B:Allopurinol 50-100mg twice to thrice daily
Sponsors
The Third People's Hospital of Chengdu
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Hospitalised patients with heart failure aged 18 years or older; 2) The diagnostic criteria for heart failure according to the 2021 and 2023 European Society of Cardiology "Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure" and its updates, as well as the "Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2018" regarding symptoms, signs, and serum biomarkers of heart failure; 3) Left ventricular ejection fraction >= 50%, NYHA heart function class II-IV; 4) Diagnostic standards for hyperuricaemia based on the 2017 "Practical Guidelines for the Diagnosis and Treatment of Hyperuricaemia in Chronic Kidney Disease" and the 2020 "Practice Guidelines for Patients with Hyperuricaemia/Gout", with uric acid levels in the past three months being male >= 420umol/L and female >= 360umol/L; 5) Voluntary participation in the trial and signing of informed consent.
Exclusion criteria
Exclusion criteria: The following conditions will exclude this trial: 1) Those who have not signed the informed consent form or have poor compliance; 2) Individuals with severe liver or kidney dysfunction, ALT/AST/ total bilirubin greater than 3 times the normal upper limit; eGFR < 30 mL/(min.1.73 m²); 3) Those with a left ventricular ejection fraction < 50%; 4) Patients with severe gout or poor response to medication; 5) Female subjects who are pregnant, breastfeeding, or have a positive pregnancy test; 6) Patients with a confirmed diagnosis of malignant tumors during the screening inclusion period or intervention follow-up period; 7) Those who have undergone or are expected to undergo ventricular de-synchronization treatment or left ventricular assist device placement within 3 months; 8) Individuals with a confirmed diagnosis of urinary system stones that have not been treated; 9) Individuals who have had an acute gout attack within the last month; 10) Patients with contraindications to the study intervention medication; 11) Those diagnosed with peripartum or chemotherapy-induced cardiomyopathy within 3 months prior to the screening inclusion period; 12) Those with acute coronary syndrome, stroke, transient ischaemic attack, or major surgeries on the heart or carotid artery such as coronary artery bypass grafting, percutaneous coronary intervention, or carotid angioplasty within 3 months prior to the screening inclusion period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All cause death or Cardiovascular death ;Heart failure rehospitalization; | — |
Secondary
| Measure | Time frame |
|---|---|
| Control rate of Hyperuricemia; | — |
Countries
China
Contacts
Public ContactJunbo Xu
The Third People's Hospital of Chengdu
Outcome results
None listed